Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011

Vaccine

Volumn 30, Issue 47, 2012, Pages 6612-6622

  Hughes, Bethan ^a   Hayden, Frederick ^b,c   Perikov, Yuri ^c   Hombach, Joachim ^c   Tam, John S ^c  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF VIRGINIA   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Broad spectrum; Cross protection; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; PLACEBO; VIRUS LIKE PARTICLE VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; MALAISE; NAUSEA; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CROSS PROTECTION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84867478343     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.073     Document Type: Conference Paper

References (77)

1. Conference website that includes the meeting agenda and list of participants. http://www.who.int/vaccine_research/diseases/influenza/meeting_16_17_Nov_2011/en/index.html.
2. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930.
3. Guideline on procedural aspects regarding a CHMP scientific opinion in the context of cooperation with the World Health Organization for the evaluation of medicinal products intended exclusively for markets outside the community. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003883.pdf.
4. Draft Guidelines on the Quality, Safety and Efficacy of Dengue Tetravalent Vaccines (Live, Attenuated). http://www.who.int/biologicals/areas/vaccines/dengue/WHO_DRAFT_Den_24May2011.pdf.
5. Treanor J.J., Hayden FG Volunteer challenge studies. Textbook of influenza 1998, 517-537. Blackwell Healthcare Communications, London, UK, [Chapter 39]. K. Nicholson, R. Webster, A. Hay (Eds.).
6. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
7. Bucasas K.L., Franco L.M., Shaw C.A., Bray M.S., Wells J.M., Niño D., et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011, 203:921-929.
8. Huang Y., Zaas A.K., Rao A., Dobigeon N., Woolf P.J., Veldman T., et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. PLoS Genet 2011, 7:e1002234.
9. Schulman J.L., Kilbourne E.D. Induction of partial specific heterosubtypic immunity in mice by a single infection with influenza A virus. J Bacteriol 1965, 89:70-174.
10. Doherty P.C., Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008, 118:3273-3275.
11. Yap K.L., Ada G.L. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol 1978, 8:413-420.
12. La Gruta N.L., Kedzierska K., Stambas J., Doherty P.C. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85:85-92.
13. Heinen P.P., Rijsewijk F.A., de Boer-Luijtze E.A., Bianchi A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002, 83:1851-1859.
14. Wesley R.D., Tang M., Lager K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 2004, 22:3427-3434.
15. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006, 24:1180-1190.
16. Laddy D.J., Yan J., Andersen H., Cohn A., Greenhouse J., Lewis M., et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009, 83:4624-4630.
17. Wiesener N., Schütze T., Lapp S., Lehmann M., Jarasch-Althof N., Wutzler P., et al. Analysis of different DNA vaccines for protection of experimental influenza A virus infection. Viral Immunol 2011, 24:321-330.
18. Pena L., Vincent A.L., Ye J., Ciacci-Zanella J.R., Angel M., Lorusso A., et al. Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J Virol 2011, 85:456-469.
19. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2(15):ra5.
20. Montastruc J.-L., Durrieu G., Rascol O. Pandemrix, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2011, 29:2010.
21. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
22. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
23. Vesikari T., Pelligrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
24. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
25. Sancho A., Melchiorri D., Abadie E More on influenza vaccine in young children. N Engl J Med 2012, 366:2528. Committee for Medicinal Products for Human Use, European Medicines Agency, [author reply 2528-9].
26. Heinonen S., Silvennoinen H., Lehtinen P., Vainionpää R., Ziegler T., Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011, 11:23-29.
27. Black S., Nicolay U., Vesikari T., Knuf M., Del Giudice G., Della Cioppa G., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30:1081-1085.
28. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
29. Belshe R.B., Gruber W.C. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000, 19:S66-S71.
30. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
31. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
32. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204:1879-1885.
33. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008, 105:5986-5991.
34. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008, 3:e3942.
35. Sui J., Hwang W.C., Wei G., Aird D., Chen L.M., Santelli E., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
36. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
37. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6:e1000796.
38. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1. [e00018-10].
39. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010, 107:18979-18984.
40. Palese P., Wang T.T. Why do influenza virus subtypes die out?. A hypothesis. MBio 2011, 2:e00150-e211.
41. Xie H., Li X., Lin Z., Jing X., Plant E., Zoueva O., et al. Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. Clin Infect Dis 2011, 53:1179-1187.
42. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respi Viruses 2009, 3:233-240.
43. Lambre C.R., Terzidis H., Greffard A., Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990, 135:49-57.
44. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2011, 28:2076-2079.
45. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521.
46. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Quirion M.R., Houser K.V., et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 2010, 5:e13162.
47. Soboleski M.R., Gabbard J.D., Price G.E., Misplon J.A., Lo C.Y., Perez D.R., et al. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS ONE 2011, 6:e21937.
48. Burt D., Mallett C., Plante M., Zimmermann J., Torossian K., Fries L. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011, 10:365-375.
49. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006, 24:254-262.
50. Langley J.M., Aoki F., Ward B.J., McGeer A., Angel J.B., Stiver G., et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 2011, 29:1921-1928.
51. Ichinohe T., Kawaguchi A., Tamura S., Takahashi H., Sawa H., Ninomiya A., et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007, 9:1333-1340.
52. Krenn B.M., Egorov A., Romanovskaya-Romanko E., Wolschek M., Nakowitsch S., Ruthsatz T., et al. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS ONE 2011, 6:e18577.
53. Nakowitsch S., Wolschek M., Morokutti A., Ruthsatz T., Krenn B.M., Ferko B., et al. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 2011, 29:3517-3524.
54. Bodewes R., Kreijtz J.H., Geelhoed-Mieras M.M., van Amerongen G., Verburgh R.J., van Trierum S.E., et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011, 85:2695-2702.
55. Hillaire M.L., van Trierum S.E., Kreijtz J.H., Bodewes R., Geelhoed-Mieras M.M., Nieuwkoop N.J., et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011, 92:2339-2349.
56. Kreijtz J.H., Bodewes R., van den Brand J.M., de Mutsert G., Baas C., van Amerongen G., et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009, 27:4983-4989.
57. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006, 193:49-53.
58. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309:13-17.
59. +. J Virol 2011, 85:11995-12000.
60. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181:4168-4176.
61. LaMere M.W., Lam H.T., Moquin A., Haynes L., Lund F.E., Randall T.D., et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011, 186:4331-4339.
62. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
63. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2010, 361:2405-2413.
64. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA 2009, 303:37-46.
65. Chen G.L., Lau Y.F., Lamirande E.W., McCall A.W., Subbarao K. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci USA 2011, 108:1140-1145.
66. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009, 106:20365-20370.
67. Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84:3312-3319.
68. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
69. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
70. Stoloff G.A., Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007, 37:2441-2449.
71. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 2010, 5(10):e13677.
72. Furuya Y., Regner M., Lobigs M., Koskinen A., Müllbacher A., Alsharifi M. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J Gen Virol 2010, 91:1450-1460.
73. Furuya Y., Chan J., Wan E.C., Koskinen A., Diener K.R., Hayball J.D., et al. Gamma-irradiated influenza virus uniquely induces IFN-I mediated lymphocyte activation independent of the TLR7/MyD88 pathway. PLoS ONE 2011, 6:e25765.
74. Alsharifi M., Lobigs M., Regner M., Lee E., Koskinen A., Müllbacher A. Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J Immunol 2005, 175:4635-4640.
75. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 2011, 6:e14538.
76. Gurwith M.J., Horwith G.S., Impellizzeri C.A., Davis A.R., Lubeck M.D., Hung P.P. Current use and future directions of adenovirus vaccine. Semin Respir Infect 1989, 4:299-303.
77. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and disease. Nat Rev Immunol 2009, 9:679-691.